Ibrigan

Timolol maleate and bimatoprost, the active ingredients in Ibrigan, are a beta‑blocker and prostaglandin analog presented as an ophthalmic solution for ocular (topical) use. They lower intra‑ocular pressure in patients with primary open‑angle glaucoma or ocular hypertension.

GNH USA supplies Ibrigan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ibrigan is used to manage conditions that involve elevated intra‑ocular pressure within the glaucoma disease family. - Primary open‑angle glaucoma: reduces intra‑ocular pressure to slow optic nerve damage. - Ocular hypertension: lowers pressure to prevent progression to glaucoma. - Patients at risk of optic‑nerve damage: helps preserve visual field by maintaining normal pressure levels.

Ibrigan may cause ocular and systemic reactions, most of which are mild and transient.

Common Side Effects: - Eye irritation or burning sensation. - Redness of the eye. - Blurred vision. - Dry eyes. - Eyelash growth. - Mild headache.

Serious or Rare Side Effects: - Severe allergic reaction (e.g., swelling, rash, difficulty breathing). - Significant decrease in heart rate or blood pressure. - Worsening of asthma or chronic obstructive pulmonary disease. - Persistent eye pain or vision loss. - Periorbital skin darkening. - Corneal edema.

Before using Ibrigan, consider the following precautions. - Cardiovascular disease: monitor heart rate and blood pressure. - Respiratory conditions: avoid use in patients with asthma or COPD. - Pregnancy and lactation: discuss risks with a healthcare professional. - Concomitant eye medications: separate instillation times to prevent interaction. - Contact lens wearers: remove lenses before and wait at least 15 minutes after application. - Store at below 25°C: keep in the original container, protect from light and moisture.

Ibrigan can interact with other medicines; awareness of the interaction level is important.

Major Interactions (Avoid): - Non‑selective beta‑blockers (systemic): may cause additive cardiovascular depression. - Sympathomimetic agents (e.g., epinephrine eye drops): can reduce Ibrigan's efficacy.

Moderate Interactions (Monitor Closely): - Carbonic anhydrase inhibitors: may enhance intra‑ocular pressure lowering effect. - Anticholinergic eye drops: could affect tear film stability. - Systemic antihypertensives: monitor for excessive blood pressure reduction.